Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

PHASE2TerminatedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

March 14, 2013

Primary Completion Date

September 14, 2017

Study Completion Date

January 30, 2020

Conditions
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell LymphomaNon-FL Indolent Non-Hodgkin's LymphomaFollicular Lymphoma
Interventions
DRUG

Entospletinib MM

Entospletinib MM tablet administered orally

DRUG

Entospletinib SDD

Entospletinib SDD tablet administered orally

Trial Locations (48)

10021

Clinical Research Alliance, New York

22031

Virginia Cancer Specialists, PC, Fairfax

23226

Virginia Cancer Institute, Richmond

27599

University of North Carolina, Chapel Hill

30046

Gwinnett Hospital System Dba The Center for Cancer Care, Lawrenceville

30060

Northwest Georgia Oncology Center, Marietta

30341

Northside Hospital, Atlanta

33021

Memorial Cancer Institute, Hollywood

33905

Florida Cancer - Colonial, Fort Myers

34471

Ocala Oncology Center, Ocala

35294

University of Alabama at Birmingham, Birmingham

37203

Tennessee Oncology, PLLC, Nashville

38138

Jones Clinic PC, Germantown

39401

Hattiesburg Clinic, Hattiesburg

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic, Cleveland

44718

Gabrail Cancer Center Research, Canton

45242

Oncology Hematology Care, Cincinnati

46202

Indiana University Simon Cancer Center, Indianapolis

48109

University of Michigan Health System, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

55404

Minnesota Oncology Hematology, PA, Minneapolis

57201

Prairie Lakes Health Care System, Inc., Watertown

60637

University of Chicago, Chicago

60714

Illinois Cancer Specialists, Niles

68130

Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha

70809

Hematology Oncology Clinic, PLLC, Baton Rouge

75230

Texas Oncology-Medical City Dallas, Dallas

76104

Center for Cancer and Blood Disorders, Fort Worth

78217

Cancer Care Network of South Texas, San Antonio

78229

Cancer Care Center of South Texas, San Antonio

78705

Texas Oncology-Austin Midtown, Austin

80218

Kaiser Permanente of Colorado, Denver

80303

Rocky Mountain Cancer Centers, LLP, Boulder

85710

Arizona Oncology Associates, Tucson

91010

City of Hope National Medical Center, Duarte

92123

Sharp Memorial Hospital, San Diego

97477

Williamette Valley Cancer Center and Research Institute, Springfield

98109

University of Washington, Seattle

98684

Northwest Cancer Specialists, PC, Vancouver

98902

Yakima Valley Memorial Hospital North Star Lodge, Yakima

99336

Columbia Basin Hematology and Oncology, Kennewick

06489

Cancer Center of Central Connecticut, Southington

02111

Tufts Medical Center, Boston

03756

One Medical Center Drive, Lebanon

07932

Summit Medical Group, P.A., Florham Park

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

H3T 1E2

Sir Mortimer B. Davis-Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01799889 - Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter